Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 19 April 1991:
Vol. 252. no. 5004, pp. 440 - 443
DOI: 10.1126/science.1708168
Prev | Table of Contents | Next

Articles

Science, Vol 252, Issue 5004, 440-443
Copyright © 1991 by American Association for the Advancement of Science

articles

Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes

L Shen, ZW Chen, MD Miller, V Stallard, GP Mazzara, DL Panicali, and NL Letvin

Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772.

Evidence indicates that cytotoxic T lymphocytes (CTLs) may be important in containing the spread of the human immunodeficiency virus (HIV) in the infected host. Although the use of recombinant viruses has been proposed as an approach to elicit protective immunity against HIV, the ability of recombinant viral constructs to elicit CD8+ CTL responses in higher primates has never been demonstrated. A live recombinant virus, vaccinia-simian immunodeficiency virus of macaques (SIVmac), was used to determine whether such a genetically restricted, T lymphocyte-mediated antiviral response could be generated in a primate. Vaccinia-SIVmac vaccination elicited an SIVmac Gag-specific, CD8+ CTL response in rhesus monkeys. These CTLs recognized a peptide fragment that spans residues 171 to 195 of the Gag protein. The rhesus monkey major histocompatibility complex (MHC) class I gene product restricting this CTL response was defined. Both the vaccinated and SIVmac-infected monkeys that shared this MHC class I gene product developed CTLs with the same Gag epitope specificity. These findings support the use of recombinant virus vaccines for the prevention of HIV infections in humans.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade.
M. Giri, K. E. Ugen, and D. B. Weiner (2004)
Clin. Microbiol. Rev. 17, 370-389
   Abstract »    Full Text »    PDF »
Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys.
S. Santra, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, C. I. Lord, R. Pal, G. Franchini, and N. L. Letvin (2002)
J. Immunol. 168, 1847-1853
   Abstract »    Full Text »    PDF »
A Commonly Recognized Simian Immunodeficiency Virus Nef Epitope Presented to Cytotoxic T Lymphocytes of Indian-Origin Rhesus Monkeys by the Prevalent Major Histocompatibility Complex Class I Allele Mamu-A*02.
S. Robinson, W. A. Charini, M. H. Newberg, M. J. Kuroda, C. I. Lord, and N. L. Letvin (2001)
J. Virol. 75, 10179-10186
   Abstract »    Full Text »    PDF »
Simian Immunodeficiency Virus (SIV) gag DNA-Vaccinated Rhesus Monkeys Develop Secondary Cytotoxic T-Lymphocyte Responses and Control Viral Replication after Pathogenic SIV Infection.
M. A. Egan, W. A. Charini, M. J. Kuroda, J. E. Schmitz, P. Racz, K. Tenner-Racz, K. Manson, M. Wyand, M. A. Lifton, C. E. Nickerson, et al. (2000)
J. Virol. 74, 7485-7495
   Abstract »    Full Text »    PDF »
Role of Immune Responses against the Envelope and the Core Antigens of Simian Immunodeficiency Virus SIVmne in Protection against Homologous Cloned and Uncloned Virus Challenge in Macaques.
P. S. Polacino, V. Stallard, J. E. Klaniecki, S. Pennathur, D. C. Montefiori, A. J. Langlois, B. A. Richardson, W. R. Morton, R. E. Benveniste, and S.-L. Hu (1999)
J. Virol. 73, 8201-8215
   Abstract »    Full Text »    PDF »
Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four Plasmodium falciparum DNA Plasmids.
R. Wang, D. L. Doolan, Y. Charoenvit, R. C. Hedstrom, M. J. Gardner, P. Hobart, J. Tine, M. Sedegah, V. Fallarme, J. B. Sacci Jr., et al. (1998)
Infect. Immun. 66, 4193-4202
   Abstract »    Full Text »    PDF »
Progress in the Development of an HIV-1 Vaccine.
N. L. Letvin (1998)
Science 280, 1875-1880
   Abstract »    Full Text »
Analysis of Gag-specific Cytotoxic T Lymphocytes in Simian Immunodeficiency Virus-infected Rhesus Monkeys by Cell Staining with a Tetrameric Major Histocompatibility Complex Class I-Peptide Complex.
M. J. Kuroda, J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin (1998)
J. Exp. Med. 187, 1373-1381
   Abstract »    Full Text »    PDF »
Vaccines against Human Immunodeficiency Virus -- Progress and Prospects.
N. L. Letvin (1993)
N. Engl. J. Med. 329, 1400-1405
   Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)